John Ruck
Family · Lynchburg, VANPI 1336688456
Payments from drug & device makers
Across 136 payments — averaging $46.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$3K
- Lifescan, Inc.$1K
- Lilly USA, LLC$510
- Dexcom, Inc.$398
- AstraZeneca$338
- Novo Nordisk$222
- plus $876 from 14 others
What the payments were for
- Consulting fees$1,06017%
- Speaking & faculty fees$2,43939%
- Food & beverage$2,83445%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 16 | $2,928 |
| Lifescan, Inc. | 1 | $1,060 |
| Lilly USA, LLC | 27 | $510 |
| Dexcom, Inc. | 20 | $398 |
| AstraZeneca | 10 | $338 |
| Novo Nordisk | 16 | $222 |
| Amarin Pharma, Inc. | 11 | $221 |
| Corcept Therapeutics | 9 | $126 |
| Ascensia Diabetes Care US Inc. | 1 | $109 |
| Boehringer Ingelheim | 7 | $105 |
| Merck | 5 | $91 |
| Zealand Pharma US, Inc. | 2 | $44 |
| IBSA Pharma Inc. | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| AbbVie | 2 | $27 |
| BD | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Bayer | 1 | $17 |
| Insulet Corporation | 1 | $16 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,333 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 141 | $236,152 |
| MounjaroTirzepatide | 106 | $231,276 |
| JardianceEmpagliflozin | 106 | $144,035 |
| TrulicityDulaglutide | 42 | $70,209 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 41 | $67,716 |
| Tresiba Flextouch U-200Insulin Degludec | 32 | $50,994 |
| JanuviaSitagliptin Phosphate | 34 | $48,476 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $44,836 |
| Tresiba Flextouch U-100Insulin Degludec | 31 | $27,158 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 18 | $24,315 |
| FarxigaDapagliflozin Propanediol | 20 | $20,999 |
| HumalogInsulin Lispro | 50 | $16,321 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 26 | $15,845 |
| Humalog Kwikpen U-100Insulin Lispro | 52 | $13,482 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 64 | $10,067 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $510 | $317,807198 claims |
| Novo NordiskOzempic, Novolog | $222 | $243,148160 claims |
| Boehringer IngelheimJardiance | $105 | $144,035106 claims |
| MerckJanuvia | $91 | $48,47634 claims |
| AstraZenecaFarxiga | $338 | $20,99920 claims |
| Sanofi-aventis U.S. LLCLantus | $2,928 | $3,17017 claims |
| AbbVieSynthroid | $27 | $63013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.
Other family in Lynchburg
- Amy StowersLynchburg$23K
- Elizabeth CopesLynchburg$23K
- Shauntell KlineLynchburg$15K
- Haley RussellLynchburg$13K
- Andrea CottonVirginia Beach$696K
- Susan MooreWytheville$438K
- Ellen WermterCharlottesville$251K
- Dana StallingsFranklin$225K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.